Relevance of the modern renal biomarkers use for the screening of early development of preeclampsia

V.V. Artyomenko, L.I. Berlinska


Pre-eclampsia is a unique multi-system disorder that occurs during the second half of pregnancy and is characterized by the arterial hypertension and proteinuria manifesting by heterogeneous disorders and adversely affecting the condition of the mother and the fetus. It has one of the leading positions in maternal and neonatal morbidity and mortality in the world. The article overviews the data on modern renal biomarkers taking into account pathogenetic kidney damage during preeclampsia. Characteristic of proposed markers used in laboratory diagnosis and researched in experiments is provided, indicating the mechanism and timing of changes of their levels in case of damage to various segments of the nephron, the correlation between the severity of kidney damage, the prospects for being used in clinical practice in each trimester of pregnancy.


pre-eclampsia; screening; renal biomarkers; pregnancy


Bagash SK, Chernichenko ІІ, Linda VA. Correction of renal function in women with gestosis. Health of woman. 2015;4(100):106-108. (in Russian).

Stokoz KYu, Lysyak DS. History of study of preeclampsia and eclampsia in obstetrics. Bulletin physiology and pathology of respiration. 2016;6(2):110-116. (in Russian).

Merkusheva LI, Kozlovskaya NL. Current ideas on the pathogenesis of renal injury in preeclampsia. Akusherstvo i Ginekologiya. 2015;(8):12-17. (in Russian).

Brytkova YaV. The diagnostic value of proteinuria and microalbuminuria in pregnant women with increased arterial pressure. RMJ. 2013;21(3):48-51. (in Russian).

Krane NK. Renal Disease and Pregnancy. Available from: Accessed: December 01, 2015.

Muller-Deile J, Schiffer M. Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy. World J Nephrol. 2014 Nov 6;3(4):169-81. doi: 10.5527/wjn.v3.i4.169.

Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011 Oct;49(8):720-8. doi: 10.3109/15563650.2011.615319.

Taran OI. Screening of some kidney diseases. News of Medicine and Pharmacy. 2016;7(580):29-32. (in Ukrainian).

Ministry of Нealth of Ukraine. Order № 676 dated December 31, 2004. On the approval of clinical protocols for obstetric and gynecological care. Available from: Accessed: December 31, 2004. (in Ukrainian).

Demirci O, Kumru P, Arınkan A, et al. Spot protein/creatinine ratio in preeclampsia as an alternative for 24-hour urine protein. Balkan Med J. 2015 Jan;32(1):51-55. doi: 10.5152/balkanmedj.2015.15447.

Inder PK, Shukla A, Gangopadhyay S, Gupta A, Sarkar G. Levels of microalbuminuria in prediction of pre eclampsia: a hospital based study. International Journal of Clinical Biochemistry and Research. 2016;3(4):354-356. doi: 10.18231/2394-6377.2016.0002.

De Geus HRH, Betje MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012 Apr;5(2):102-108. doi: 10.1093/ckj/sfs008.

Vel'kov VV. Cystatin C and NGAL — the markers of preclinical renal dysfuction and subclinical acute kidney injury. Laboratornaya sluzhba. 2015;4(2):38-43. (in Russian).

Padma Y, Aparna V B, Kalpana B, Ritika V, Sudhakar PR. Renal markers in normal and hypertensive disorders of pregnancy in Indian women: a pilot study. Int J Reprod Contracept Obstet Gynecol. 2013;2(4):514-520. doi: 10.5455/2320-1770.ijrcog20131205.

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. PMID: 19414839.

Niraula A, Lamsal M, Baral N, et al. Cystatin-C as a marker for renal impairment in preeclampsia. J Biomark. 2017;2017:7406959. doi: 10.1155/2017/7406959.

Gong S, Cai Y, Su G. Value of serum cystatin C level in assessing renal damage in preeclamptic patients. Nan Fang Yi Ke Da Xue Xue Bao. 2013 Sep;33(9):1386-9. PMID: 24067226. ( in Chinese).

Digambarrao GD, Pramod IW, Varsha BH. Cystatin C in preeclampsia: A case control study. International Journal of Current Research. 2015;7(7):18226-18230.

Trifonova AN, Ostrovskiy OV, Verovskiy VE, Kareva AA. Analytical and clinical aspects of measuring urinary cystatin C levels in pregnant women. Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta. 2016;4(60):121-123. (in Russian).

Petermann A, Floege J. Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract. 2007;106(2):c61-6. doi: 10.1159/000101799.

Penning ME, Bloemenkamp KW, van der Zon T, et al. Association of preeclampsia with podocyte turnover. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1377-1385. doi: 10.2215/CJN.12811213.

Aita K, Etoh M, Hamada H, et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 2009;112(2):c65-70. doi: 10.1159/000213083.

Jim B, Jean‑Louis P, Qipo A, et al. Podocyturia as a diagnostic marker for preeclampsia amongst high‑risk pregnant patients. J Pregnancy. 2012;2012:984630. doi: 10.1155/2012/984630.

Craici IM, Wagner SJ, Bailey KR, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013 Jun;61(6):1289-96. doi: 10.1161/HYPERTENSIONAHA.113.01115.

Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89-94. doi: 10.1080/00365510802150158.

Karampas G, Eleftheriades M, Panoulis K, et al. Maternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate: a longitudinal study. Prenat Diagn. 2014 Aug;34(8):726-33. doi: 10.1002/pd.4337.

D’Anna R, Baviera G, Giordano D, et al. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn. 2009 Nov;29(11):1066-8. doi: 10.1002/pd.2339.

D’Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand. 2008;87(12):1370-3. doi: 10.1080/00016340802464463.

D’Anna R, Baviera G, Giordano D, et al. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand. 2010;89(2):275-8. doi: 10.3109/00016340903443676.

Kim SM, Park JS, Norwitz ER, et al. Circulating levels of neutrophil gelatinase–associated lipocalin (NGAL) correlate with the presence and severity of preeclampsia. Reprod Sci. 2013 Sep;20(9):1083-1089. doi: 10.1177/1933719113477480.

Simonazzi G, Capelli I, Curti A, Comai G, Rizzo N, La Manna G. Serum and urinary neutrophil gelatinase-associated lipocalin monitoring in normal pregnancy versus pregnancies complicated by preeclampsia. In Vivo. 2015 Jan-Feb;29(1):117-21. PMID: 25600539.

Dorofeykov VV, Kerkeshko GO. Prospects of laboratory diagnostics in obstetrics (according to the materials of the 20-th European Congress of clinical chemistry and laboratory medicine, EuroMedLab 2013). Journal of obstetrics and woman disease. 2013;62(4):116-119. (in Russian).

Pihl K, Sørensen S, Jørgensen FS. P 35 First trimester maternal serum neutrophil gelatinase-associated lipocalin (NGAL) in prediction of preeclampsia in nulliparous women. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2017 July; 9:52-53. doi: 10.1016/j.preghy.2017.07.113.

Tekkeşin N, Ayar A. Maternal urinary NGAL levels for diagnosis of preeclampsia in pregnant woman: a protential diagnostic biomarker. Nobel Med. 2015;11(3):37-41. (in Turkish).

Ødum L, Andersen AS, Hviid TV. Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion increases in normal pregnancy but not in preeclampsia. Clin Chem Lab Med. 2014 Feb;52(2):221-5. doi: 10.1515/cclm-2013-0547.

Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008 May;118(5):1657-68. doi: 10.1172/JCI34487.

Wang Y, Gu Y, Loyd S, Jia X, Groome LJ. Increased urinary levels of podocyte glycoproteins, matrix metallopeptidases, inflammatory cytokines, and kidney injury biomarkers in women with preeclampsia. Am J Physiol Renal Physiol. 2015 Dec 15;309(12):F1009-17. doi: 10.1152/ajprenal.00257.2015.



  • There are currently no refbacks.

Copyright (c) 2018 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2018


   Seo анализ сайта